Enhanced CTLA-4 blockade: A Deep Dive in Targets for Cancer IO

When:  Oct 5, 2022 from 13:00 to 15:00 (CT)
This webinar, the seventh of the 2022 Targets for Cancer IO: A Deep Dive Series, will discuss the research and clinical findings behind the enhanced blockade of cytotoxic T lymphocyte antigen-4. Basic, clinical and translational researchers in academia and industry and members of the investment community are the target audience of this series.

Moderators:
  • James P. Allison, PhD, FAIO – The University of Texas MD Anderson Cancer Center
  • Alan J. Korman, PhD, FAIO – Vir Biotechnology
Faculty:
  • TBD

Learn more about the 2022 Targets for Cancer IO: A Deep Dive Series here!

Targets for Cancer IO: A Deep Dive Series is supported, in part, by educational grants from Genmab, US, Inc. and Merck & Co., Inc. (as of 6/6/2022).

#TargetsforCancerImmunotherapyADeepDiveSeminarSeries #NoCEOffered #Industry #Researcher #2022
Event Image

Contact



education@sitcancer.org

Related Content